EAU Guidelines Upgrade Aquablation® Therapy to Strong Surgical Recommendation for BPH

Updated European Association of Urology guidelines reflect growing clinical evidence supporting Aquablation therapy in the surgical treatment of benign prostatic hyperplasia March 23, 2026 07:00 ET  | Source: PROCEPT BioRobotics SAN JOSE, Calif., March 23, 2026 (GLOBE NEWSWIRE) — PROCEPT BioRobotics® (Nasdaq: PRCT) today highlighted the latest update to the European Association of Urology (EAU) Guidelines for male […]

Philips convenes the Annual General Meeting of Shareholders 2026

March 23, 2026 05:30 ET  | Source: Royal Philips March 23, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has convened the Annual General Meeting of Shareholders (AGM) 2026 and published the agenda with explanatory notes. As previously announced, the agenda includes: The agenda furthermore includes a proposal

Philips proposes new appointment and re-appointments to its Supervisory Board and CEO re-appointment

March 23, 2026 04:30 ET  | Source: Royal Philips March 23, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced a proposed Supervisory Board appointment and re-appointments, in addition to the previously announced proposal to re-appointment its President/CEO. The Supervisory Board will submit to the Annual General Meeting of Shareholders

Teva Releases Q1 2026 Aide Memoire

March 19, 2026 16:30 ET  | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, March 19, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2026 Aide Memoire is available on the “Investors” page on its website. Q1 2026 Aide Memoire Teva has compiled this document with public information that was

Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026

March 19, 2026 16:30 ET  | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel and PARSIPPANY, N.J., March 19, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2026 financial results on Wednesday, April 29, 2026, at 7:00 a.m. ET. Following

Curia Expands Glasgow Manufacturing Capacity and Enhances Cell Line Development Platform

March 19, 2026 09:00 ET  | Source: Curia Global, Inc. ALBANY, N.Y., March 19, 2026 (GLOBE NEWSWIRE) — Curia, a leading contract research, development and manufacturing organization (CDMO), today announced progress on the expansion at its Glasgow, UK sterile drug product facility as well as enhancements to its proprietary platform for cell line development. The Glasgow, UK,

Tilray Medical Announces Major Expansion of Medical Cannabis Portfolio in Australia

March 19, 2026 07:00 ET  | Source: Tilray Brands, Inc. NEW YORK and SYDNEY, March 19, 2026 (GLOBE NEWSWIRE) — Tilray Medical, a recognized global leader in medical cannabis and a division of Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), today announced its largest portfolio expansion in Australia to date. The expanded medical cannabis offering reinforces

SK pharmteco Reaffirms Three-Business-Unit Strategy, Strengthens Global Gene Therapy Business Unit with Funding Commitment

March 19, 2026 04:00 ET  | Source: SK pharmteco Inc. RANCHO CORDOVA, Calif., March 19, 2026 (GLOBE NEWSWIRE) — SK pharmteco today announced a significant funding commitment to support strategic initiatives within its viral vector business, while reaffirming its long-term growth strategy across three business units: small molecule, peptides, and viral vectors. SK pharmteco is sharpening its

AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors

AIM also intends to pursue Japanese Orphan Drug Designation for Ampligen in treatment of pancreatic cancer March 18, 2026 08:36 ET  | Source: AIM ImmunoTech Inc. OCALA, Fla., March 18, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Japan Patent Office has fully approved a Japanese patent covering the Company’s

Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting

Four presentations deliver new insights into zanidatamab, including its differentiated HER2 biology March 18, 2026 07:46 ET  | Source: Zymeworks Inc. VANCOUVER, British Columbia, March 18, 2026 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that the

Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting

March 17, 2026 17:02 ET  | Source: Zymeworks Inc. VANCOUVER, British Columbia , March 17, 2026 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the acceptance of an oral presentation and six abstracts from its wholly-owned R&D

Adagene’s Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA

March 17, 2026 16:35 ET  | Source: Adagene Inc. SAN DIEGO and SUZHOU, China, March 17, 2026 (GLOBE NEWSWIRE) — Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that muzastotug will be highlighted in two poster presentations at this year’s AACR Meeting, taking place

Alamar Biosciences Launches NULISAseq™ Neuro 220 Panel, its largest precision proteomics panel with the sensitivity and specificity to advance neurological disease research

New panel expands coverage for Alzheimer’s and Parkinson’s diseases including 15 new biomarkers developed with support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and 12 assays specific to brain and peripheral Tau isoforms | NULISA™ data to be presented in over 11 scientific sessions and 25 posters at the International Conference on

SK pharmteco Announces Successful FDA Inspection of Small Molecule Manufacturing Facility in La Porte, Texas

March 17, 2026 09:03 ET  | Source: SK pharmteco Inc. RANCHO CORDOVA, Calif., March 17, 2026 (GLOBE NEWSWIRE) — SK pharmteco today announced the successful conclusion of a regulatory inspection of its small molecule North America facility in La Porte, Texas. The U.S. Food and Drug Administration (FDA) carried out a general inspection of the site from February 9

Scroll to Top